Concert Pharmaceuticals, Inc. (CNCE) Stock Price, Financial Report, & Fundamental AnalysisNASDAQ:CNCE
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
Concert Pharmaceuticals, Inc. Fundamental Analysis
Net Income Growth
CNCE has had growing net income for the last 3 years
Price to Book (PBV) Ratio
Overvalued price-to-book. CNCE stock price is overvalued by more than 1x the price-to-book value.
Debt-Equity Ratio (DER)
CNCE equity is higher than it's debt.
CNCE has positive revenue for last 5 years
Small market capitalization. Market capitalization is less than 2bn USD
CNCE has never had growing revenue.
CNCE never has positive net income for 2 years.
CNCE has low dividend yield (0%).
Return of Assets
CNCE has low return of asset (-39.5%).
Return of Equity
CNCE has low return of equity (-60.1%).
Return of Invested Capital
CNCE has low ROIC.
Concert Pharmaceuticals, Inc. Financials
Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.
Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.
- 32,578 USD
- 0 USD
- Net Income
- -80,051 USD
- Profit Margin
A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.
- Free Cash Flow
- -55,409,000 USD
Liquidity & Solvency
Solvency refers to an company's capacity to meet its long-term financial commitments. Liquidity refers to an company's ability to pay short-term obligations. The term also refers to a company's capability to sell assets quickly to raise cash.
Short Term Liabilities
Long Term Liabilities
|Dividend Payout Ratio (DPR)||0%|
|Dividend Payout Ratio (DPR)||0%|
|Dividend per Share||0,00 USD|
|Price to Earning (PER)||-1.8x|
|Price to Earning-Growth (PEG)||0x|
|Price to Book Value (PBV)||0x|
|Debt-Equity Ratio (DER)||28.41%|
|Net Profit Margin (NPM)||-119465.25%|
|Return of Assets (ROA)||-39.5%|
|Return of Equity (ROE)||-60.1%|
|Return on Capital Employed (ROCE)||-80.83%|
|Days of Sales Outstanding (DSO)||10631.69|
|Days of Inventory Outstanding (DIO)||0|
|Days Payable Outstanding (DPO)||0|
|Operating Cycle (OC)||0|
|Cash Conversion Cycle (CCC)||0|
Concert Pharmaceuticals, Inc. Executives
- CEO Name
- Dr. Roger Tung
Concert Pharmaceuticals, Inc. Profile
About Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
- Company name
- Concert Pharmaceuticals, Inc.
- NASDAQ Global Market
65 Hayden Ave Ste 3000N